Citi has issued a research report stating that China Life (02628) remains ahead of its peers on new business value (NBV) for the first nine months, while net profit was weighed down by investment and came in broadly in line with expectations. The broker maintained its "Buy" rating with a target price of HK$37.7.
China Life reported results for the first nine months of 2026, with new business value (NBV) rising 13% year on year, still leading the industry. Net profit fell 47% year on year to RMB 89.4 billion, mainly dragged down by investment, broadly matching expectations. Operating profit (OPAT) rose 16% year on year to RMB 94.2 billion, an acceleration from the 13% growth seen in the first half. Book value expanded 10% over the first nine months.
The bank noted that, in line with the industry, third-quarter NBV growth slowed markedly due to a high base and disruption from regulatory changes in the bancassurance channel, but management remains confident about agency and bancassurance channel sales in the fourth quarter of this year and the first quarter of next year.
First-year premiums for the first nine months were roughly flat year on year at RMB 217 billion, while third-quarter first-year premiums fell 35% year on year to RMB 37 billion. The product mix shifted toward regular premiums, with first-year regular premiums growing relatively quickly in the first nine months, up 6%. The number of agents rose 1% quarter on quarter to 616,000 at the end of the third quarter, outperforming peers. On bancassurance, management said the company led the industry in first-year premiums and first-year regular premiums through the bancassurance channel in the first nine months, thereby expanding its market share.
Comments